rnatics develops therapeutics that target disease-causing RNAs in tissue macrophages, which provide tremendous therapeutic opportunities for multiple diseases.
To employ the unique natural phagocytic properties of tissue resident macrophages as an effective means of delivery to gain access to organs previously not accessible to nucleic acid therapeutics.
RNA-targeted therapeutics hold great promise and evolve rapidly towards clinical application. Except for the liver, the principle bottleneck of all nucleic acid therapeutics remains their insufficient delivery to their target organs. All human organs contain a population of tissue resident macrophages that self-renew and execute manifold and key roles in tissue homeostasis and organ disease. These tissue macrophages are designed by nature for high capacity uptake of specific higher molecular weight structures.
Proprietary macrophage-targeting technologies to deliver nucleic acid therapeutics to tissue resident MPs.
Stefan Engelhardt is an internationally renowned expert in non-coding RNA research and has contributed several landmark studies as to their role in disease. He holds a specialist degree in Pharmacology and is full professor and director of the Institute of Pharmacology and Toxicology at Technical University of Munich (TUM) since 2008. Stefan Engelhardt has founded - and served from 2010-2020 as its speaker - the Munich Heart Alliance, the Munich site of the German Centre for Cardiovascular Research (DZHK), where S. Engelhardt is also member of the steering board. He is speaker of the DFG-Sonderforschungsbereich (SFB-TRR267) on Non-coding RNAs in the cardiovascular system, established in 2019. S. Engelhardt served as Vice Dean for Research for TUM School of Medicine from 2013-2019.
Thomas Frischmuth holds >30 years of experience in the life science and medical device field as researcher, advisor, consultant and in management position. His research activities range from chemical synthesis (small to large scale) and analyses, molecular and cell biology, biotech synthesis (small and large scale), diagnostic, medical device, drug and treatment development. Until now, Thomas Frischmuth developed and evaluated 6 drugs pre-clinically and brought 4 of them into clinical evaluation studies Phase I and II. One drug is marketed for cancer treatment.
In 2003 Thomas Frischmuth founded his own private venture fund company (Gradus Venture GmbH) and invested in total into 6 companies of which one was de-vested and one partially. Before rnatics GmbH, Thomas Frischmuth co-founded 3 companies, metaSysX GmbH in Potsdam-Golm (2012), Protagen Protein Services GmbH in Heilbronn (2013) and Evidentic GmbH (2017). Overall the companies employ now more than 180 employees and have revenues above 30 Mio. Euro per annum. In 2009 Thomas Frischmuth invested into baseclick GmbH and became its CEO. He co-invented serval click chemistry tools and products including COVID-19-related technologies, such as a Next Generation Sequencing SARS-CoV-2 kit and a second generation mRNA SARS-CoV-2 vaccine.
Klaus F. Rabe has a track record of approximately 25 years in clinical research in pulmonary medicine and has been the coordinating investigator of several drug development programs and pivotal trials. He published more than 500 publications in the field of pulmonary medicine.
Klaus F. Rabe is the CMO and medical director of LungenClinic Großhansdorf GmbH, one of the largest clincal centres on respiratory disease in Germany and heads the department of Pulmonary Medicine. He is currently co-director of the German Center for Lung Research (DZL) and member of the steering committee of the Exzellenzcluster Präzisionsmedizin für chronische Entzündungserkrankungen (PMI). He served as president of the European Respiratory Society and the German Society for Pulmonology, and together with colleagues was awarded the Balzan price in 2019 for his translational pulmonary research.